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Background: Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) in Cystic Fibrosis (CF) and the impact on CF disease progression
are still under debate.
The objectives of this study were to determine clinical variables associated with MRSA colonization and examine impact on FEV1 evolution in
CF patients.
Methods: A retrospective case–control study using the University Hospital of Brussels CF clinic patient registry from 2002 to 2010, comparing
clinical variables and decline of FEV1 of MRSA positive patients with age and sex matched controls, chronically colonized with S. aureus.
Results: Thirty of the 165 CF patients, chronically colonized with S. aureus, had cultures positive for MRSA (18.2%). Excluding patients under
4 years, the prevalence became 15.2% (23/151). Chronic colonization (i.e., three or more consecutive positive cultures) was found in 19/151
(12.6%).
The MRSA positive group showed a higher proportion of patients with genotype F508del, less pancreas sufﬁcient patients, more bronchiectasis
and more frequent hospitalization.
The FEV1 recorded one year prior to, and at the moment of MRSA acquisition, was lower but not signiﬁcantly different from that obtained in
controls (72.9%±26.6 vs 84.3±21.8 and 68.2%±27.1 vs 81.4%±24.3 respectively, pN0.1). However, FEV1 decline over 2- and 6-year periods,
were signiﬁcantly greater in the chronic MRSA group than in the controls (−5%±5.5 vs −2.5±2.3 over 2 years (p=0.043) and −1.8%±4.6 vs
−1.0%±1.9 over a 6-year period (p=0.026)).
Conclusion: In our center the prevalence of MRSA in CF patients, chronically colonized with S. aureus and over the age of 4 years, was 15.2%
(12.6% chronic infection). MRSA colonization was shown to be associated with a genotype F508del, presence of bronchiectasis and hospitalization.
Our spirometric data also show that a MRSA episode entails an FEV1 decline that is almost double that predicted for CF patients who can remain
unaffected by MRSA.
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doi:10.1016/j.jcf.2011.08.006progressive respiratory damage, which almost inevitably leads to
respiratory failure and death. With increasing survival due to
improvements of care, an increased frequency of pulmonary
infections with new and resistant pathogens has been identified
[1]. In particular, the prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) in respiratory cultures of CF pa-
tients has increased over the past decade. Previous reports have
documented the prevalence of MRSA in CF patients, someby Elsevier B.V. All rights reserved.
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national survey performed in nine CF centers found a prevalence
of MRSA colonization of 5% (range 0% to 17%) [10].
Little is known about the risk factors for acquisition of MRSA;
and the impact of chronic MRSA colonization on lung function
and exacerbation rate remains uncertain. On the one hand, the pres-
ence of MRSA in any given patient could be an indication of more
severe lung disease, making the patient more prone to MRSA in-
fection. This predisposition to MRSA infection could be related
to one or several aspects of disease severity in CF, such as presence
of bronchiectases and/or grossly impaired lung function. On the
other hand, the possibility of enhanced lung function decline subse-
quent to MRSA colonization remains controversial. Previous stud-
ies have failed to reach consensus on these issues of risk and
impact of MRSA in CF [2,3,5,6,11,12]. Very recently,
Dasenbrook et al. [11] showed a worse survival in patients with
MRSA colonization of the respiratory tract, even after controlling
for several factors associated with severity of illness.
To understand the risk factors for acquisition of MRSA in CF
patients will aid the expansion of effective preventive strategies.
Hence, we conducted a retrospective case–control study, to first
assess prevalence of MRSA in a cohort of patients, chronically
colonized with S. aureus, having visited our CF clinic over the
past decade. The second goal was to characterize these patients
in terms of various aspects of disease severity at the time of
MRSA diagnosis, and compare those to matched CF controls,
chronically colonized with S. aureus, but who never acquired
MRSA. The third goal was to investigate short and long term
evolution of spirometry in the chronic MRSA group, considering
an observation period starting from one year prior to MRSA
acquisition.
2. Patients and methods
We conducted a retrospective case–control study using the pa-
tient registry from the CFClinic of the University Hospital of Brus-
sels spanning the years 2002–2010 (a total of 247 patients were
followed-up in our center in this time period). Approval was
obtained from local ethics committee. From the 2002–2010 patient
registry, all CF patients known with S. aureus positive cultures
were retrieved. MRSA status was determined from respiratory
tract cultures (obtained from sputum or throat swabs). Chronic in-
fection was defined as having three or moreMRSA cultures during
at least 6 months follow-up. From this MRSA subgroup, all
patients under the age of 4 were excluded to avoid unreliable
spirometric results for the purpose of this study. A control group
was then sought from the same pool of CF patients with S. aureus
sensitive to methicillin, and matching each MRSA patient for
gender and age. We also verified that all relevant data for each
age and gender matched control patient were available for a time
point which differed by no more than 2 months from the
corresponding time of MRSA diagnosis in the MRSA group.
We determined the patient's bodymass index (BMI), retrieved
all relevant data on genotype, pancreatic function (where pancre-
atic insufficiency was defined by pancreatic enzyme treatment
and fecal elastase below 15 μg/g feces), and presence of CF
related diabetes (CFRD) mellitus for all patients (or equivalenttime point in the control group). We also inspected the patient
files for Pseudomonas aeruginosa colonization and bronchiecta-
sis already present at the time of MRSA diagnosis. Finally, we
checked whether patients had been hospitalized in the year pre-
ceding MRSA diagnosis. None of the patients were chronically
colonized with Burkholderia cepacia complex. Transplant and
death in the period subsequent to MRSA (or equivalent time in
controls) was also documented.
In order to quantify short and long term longitudinal
variations in spirometry, we considered FEV1 measurements
along the following timeline: 1 year prior to MRSA diagnosis,
at time of MRSA diagnosis, 1 year after MRSA diagnosis,
and after maximal follow-up time (and equivalent times in the
control patients). Note that maximal follow-up time differed
between patients for a variety of reasons, such as: lung
transplant, death, or patients having acquired MRSA towards
the end of the registry period under consideration.
2.1. Statistical analysis
All data were analyzed with non-parametric tests, using
MedCalc (v10.4; Mariakerke; Belgium). Mann Whitney U
tests were performed to test for differences in BMI and FEV1
between MSRA and control groups. The significance of any
changes in FEV1 within each group was tested with Wilcoxon
tests. Categorical parameters (CFRD, pancreatic function,
bronchiectasia, genotype, chronic P. aeruginosa infection)
were examined using the Fisher exact test. Statistical
significance was accepted at pb0.05.
3. Results
From the 2002–2010 CF patient registry, 165 patients could
be retrieved on basis of chronic S. aureus colonization. Of these
165 patients (age range 4–57 years), 30 (18.2%) were identified
as having respiratory cultures positive for MRSA at some point
in time. When excluding all patients younger than 4 years for
the purpose of the present study, the CF population with S.
aureus decreased to 151 patients, and MRSA prevalence in
this subgroup became 15.2% (23/151). Of the 23 CF patients
constituting the MRSA group, 19 had chronic infection (three
or more MRSA cultures during at least 6 months follow-up);
thus, prevalence of chronic colonization in the patient
population aged over 3 years amounted to 12.6%. This
subgroup of 19 patients with chronic MRSA infection was
used for further analysis.
Table 1 summarizes the characteristics of these 19 patients.
While the control patients were matched to the MRSA patients
only for age and gender, body mass index turned out to not be
significantly different between both groups either. The most
apparent differences between the groups were: a higher
proportion of patients in the MSRA group of genotype
F508del (c(1679+94–2619+986del8118)), none of the MRSA
patients were pancreas sufficient, and more MRSA patients
had bronchiectasis. Although we saw a higher proportion of
CFRD and chronic P. aeruginosa infection, the observed
differences between the two groups, did not reach statistical
Table 1
Characterization of all patients with chronic MRSA and a group of age – gender
matched controls.
MRSA group Control group P
value
n=19 n=19
M/F 9/10 9/10
Mean age 20.3±12.3 20.3±12.3 N0.1
Body mass index 18.4±3.0 20.3±5.1 N0.1
Pancreatic insufficiency 19 13 0.020
CFRD 7 4 N0.1
Pseudomonas aeruginosa 12 8 N0.1
F508del 15 8 0.045
Bronchiectasis 19 12 0.008
Hospitalization the year preceding
MRSA
15 8 0.045
Death after MRSA diagnosis 2 0 N0.1
Transplant after MRSA diagnosis 2 2 N0.1
FEV1 one year prior to MRSA diagnosis 72.9%
±26.6%
84.3%
±21.8%
N0.1
FEV1 at MRSA diagnosis 68.2%
±27.1%
81.4%
±24.3%
N0.1
FEV1 1-year post MRSA diagnosis 65.2%
±23.2%
80.6%
±24.8%
0.016
Short term FEV1 change (over 2 years) −5.0%
±5.5%
−2.5%
±2.3%
0.043
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patients from the MRSA group had been subject to hospitaliza-
tion more frequently than the control group.
Despite the fact that average FEV1 one year prior to MRSA
diagnosis, and average FEV1 at the moment of MRSA diagno-
sis, were more than 10%pred lower in the chronic MRSA group
compared to the control group, the FEV1 differences between
both groups did not reach statistical significance (72.9%
±26.6 vs 84.3±21.8 and 68.2%±27.1 vs 81.4%±24.3 respec-
tively; pN0.1). However, one year after MRSA diagnosis,
FEV1 was significantly lower in the chronic MRSA versus con-
trol group (65.2%±23.2 vs 80.6%±24.8; p=0.016).
The short and long term decline in FEV1 can be better
appreciated from Fig. 1, where individual time-course is plotted
versus actual time prior to, or following, MRSA diagnosis (t=0
in the plot). In order to cancel out FEV1 inter-subject variability
in either group at baseline (considered here as one year prior to
MRSA diagnosis), data are represented as an individual change
in FEV1 with respect to each patient's baseline value, i.e.,
ΔFEV1 (in %predicted) equals FEV1 obtained at any point in
time, minus FEV1 obtained one year prior to diagnosis. Solid
lines are the short term changes in the 2-year time frame spanning
one year before to one year after MRSA diagnosis. Within each
group, Fig. 1 shows considerable heterogeneity of FEV1 change
between one year prior to and the time of diagnosis. The short
term FEV1 change, being the FEV1 decline per year in the 2-
year time frame around MRSA diagnosis, was −5.0%pred per
year in the chronic MRSA group, versus only −2.5%pred per
year in the control group (p=0.043; Mann Whitney U test).
From visual inspection of the time evolution of FEV1 recorded
over periods exceeding 1.5 years after MRSA diagnosis (dashed
lines in Fig. 1), it can be seen that overall decline is greater in
the MRSA group. Average time interval over which longerterm FEV1 changes could be considered was 6.1±2.1(SD)
years in the MRSA group and 6.0±2.1(SD) years in controls.
When computing individual long term FEV1 change as the
FEV1 decline per year in the time frame spanning one year before
to the longest follow-up FEV1 measurement on each patient, long
term FEV1 decline amounted to −1.8%pred per year in the
chronic MRSA group, and −1.0%pred per year in the controls;
the rate of FEV1 decline in the chronic MRSA group versus
control was significant (p=0.026; Mann Whitney U test).
None of the MRSA positive patients received eradication
treatment during the study period. Nevertheless, when hospitalized
for infectious exacerbation, the patients received standard anti-
MRSA treatment (i.e. glycopeptides as vancomycin 1 g twice
daily intravenously or linezolid 600 mg twice daily orally in case
of vancomycin resistance or intolerance). Until now we did not
use decolonization therapies (in case of nasal carriage) with topical
antibiotics to reduce the risk of self-infection or transmission in our
center.
Over the course of the observation period two patients died
of respiratory insufficiency, both of these in the MRSA group
(indicated by crosses in Fig. 1A). Furthermore, in both groups
two patients underwent bilateral lung transplantation (indicated
by open circles in Fig. 1A and B).
4. Discussion
The prevalence of MRSA positive cultures in our population,
known with S. aureus colonization, was 15.2%; and chronic
colonization (i.e., three or more consecutive cultures) was found
in 12.6% of our population. It has been observed that MRSA
prevalence in CF has increased in recent years, from 0.1% in
1995 to 22% in 2007 according to one report [7], and that
prevalence is greater in CF patients over 18 years old (16%)
than in younger patients (10%) [6]. It must be highlighted that
the 22% prevalence noted in the Annual Report of the Cystic
Fibrosis Foundation is derived from a different population than
in our study (whole group of US Cystic Fibrosis patients, not
only those colonized with MSSA) [7]. The 13% chronic MRSA
prevalence value found here in CF population chronically
colonized with S. aureus ranging 4–57 years, is in line with
those prevalence values reported by others that relate to observa-
tion periods after 2000. This prevalence ranged 10–19% [5–
7,13] as opposed to much smaller numbers in studies examining
CF patients prior to 2000, showing a rather consistent 3%
[2,3,14]. There is one report of a similarly low prevalence despite
being derived from a recent CF population (3%), but the patient
characteristics of this study are not specified [13]. A Belgian na-
tional survey, performed in nine specialized CF centers (includ-
ing ours), found widely varying prevalences from 0 to 17%
[10]. Surely, variability in prevalence numbers will also be
influenced by local hospital policies (e.g., use of antibiotics,
eradication protocols, segregation measures, barrier nursing),
and geographic differences in antibiotics susceptibility.
As could be expected, acquisition and chronic colonization of
MRSA was associated with hospitalization in the year previous
to the MRSA infection (Table 1), as also shown by Nadeslingam
et al. [15] and Ren et al. [6]. Although MRSA is still mainly
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Fig. 1. Short and long term evolution of each patient's FEV1 change versus individual baseline FEV1 in the chronic MRSA group (panel A) and controls (panel B)
(see text for details). All data points are plotted versus actual time prior to, or following the time of MRSA acquisition (which corresponds to t=0). Solid lines show
the short term changes in the 2-year frame spanning one year before to one year after MRSA diagnosis. Dotted lines connect the 1-year post MRSA values with those
obtained after the longest follow-up period available for each patient. Open circles and crosses indicate patients who underwent bilateral lung transplantation or died
after the last FEV1.
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different strains of MRSA. Some are known to cause outbreaks
in hospital setting, referred to as Epidemic MRSA or EMRSA.
Community-acquired MRSA (CA-MRSA) is defined as any
MRSA acquired by a person who has had no contact with hos-
pitals or has no other healthcare-associated risk factors. Yet, this
does not exclude the possibility that this strain is in fact a hos-
pital strain that has been spread between people in the com-
munity. Therefore a molecular definition of CA-MRSA is more
reliable to confirm its origin. ThemecA gene is carried on a mobile
genetic element, the Staphylococcal Cassette Chromosome (SCC)
mec. If the strain is SCCmec type IV or V and is genetically unre-
lated to known hospital strains it is classified as CA-MRSA
(Kluytmans-VandenBergh and Kluytmans) [16,17]. Recent new
strains from the community have emerged, typically expressing
the virulence factor, Panton-Valentine Leucocidin (PVL) andcausing fatal necrotizing pneumonias [18]. We did not perform
molecular analysis on the MRSA strains used in this study.
Our CF patients in the MRSA group were also characterized
by two factors which clearly distinguished them from the
control patients: genotype F508del and the presence of
bronchiectasis (Table 1). It could be argued that both are
associated with more severe lung disease. Indeed, patients with
the F508del genotype generally present with a more severe CF
phenotype [19]. The presence of bronchiectasis is also a known
marker of more severe lung destruction, possibly making these
patients more at risk for colonization with resistant bacteria.
Our patients known with chronic S. aureus colonization are trea-
ted routinely with narrow spectrum antibiotics, such as flucloxa-
cillin, whenever S. aureus grows from respiratory cultures.
In summary of the clinical findings, we could state that time
spent in hospital, genotype, pancreatic insufficiency and pre-
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for acquisition of MRSA. Although we also saw a higher propor-
tion of CFRD and chronic P. aeruginosa colonization, the
observed differences between the two groups did not reach
statistical significance.
In the past, several studies have examined possible risk factors
for MRSA acquisition, yet have failed to draw firm conclusions,
possibly because of the underlying variability in patient
characteristics and the time periods under study. Boxerbaum et
al. [2] found no differences in clinical score or hospitalization fre-
quency between CF patients with or without MRSA. Miall et al.
[3] found no difference in clinical score or use of antibiotics in the
year prior to MRSA infection, but did obtain a statistical
significant difference in radiological score and use of antibiotics
in the following year after acquisition of MRSA (this cohort con-
sisted of children under the age of 16 years). Giron et al. [5]
showed no difference in pancreatic function, clinical or radiolog-
ical scores between the patients with or without MRSA, but noted
significantly more exacerbations in the year prior to the infection.
Finally, Ren et al. [6] demonstrated more hospitalization and use
of antibiotics in the year prior to the infection, and also observed a
significantly lower FEV1 in the MRSA infected patients (of the
order of 10%pred lower). The magnitude in FEV1 differences is
very similar to the differences in average FEV1 observed here be-
tween MRSA and control groups (Table 1), which did not reach
statistical significance one year prior to, nor at the time of,
MRSA diagnosis.
We did not observe a statistical significant difference in
FEV1 values between MRSA and control groups one year
prior to MRSA infection, which may not be surprising given
the heterogeneity of the CF patient population in general in
terms of FEV1 and the small number of patients. Hence, on
basis of our results in a study population that was limited in
number, it seems unlikely that FEV1 will provide any predictive
value of which CF patient is more likely to get infected with
MRSA. There was a considerable heterogeneity in FEV1
change between one year prior to and the time of diagnosis.
However, one year after MRSA diagnosis, FEV1 had become
significantly lower in the chronic MRSA versus the control
group. We therefore quantified the rate of FEV1 decline,
which is an important outcome measure because it is closely re-
lated to morbidity and mortality in CF [20].
The impact of chronic MRSA infection on FEV1 has also
been studied by Dasenbrook et al. [12], who suggested that it
is associated with a more rapid decline in FEV1 in patients
aged 8–21 years. Determined over an average follow-up period
of 5.3 years, the rate of FEV1 decline was 2.1%pred per year in
children with chronic MRSA and 1.4%pred per year in con-
trols. These data can be directly compared to our long term
FEV1 declines determined over 6 years, i.e., 1.8%pred per
year in the chronic MRSA group and 1.0%pred per year in
the control group. In fact, we observed here that both the
short term and long term FEV1 decline, determined over re-
spectively 2 and 6 years, were significantly greater in the
chronic MRSA group. Dasenbrook et al. could also demon-
strate a clear association between MRSA and worse survival
in patients with CF, even after controlling for several factorsassociated with disease severity [11]. Taken together our results
suggest an association between chronic MRSA colonization
and lung function decline.
The degree of FEV1 decline found in chronic MRSA pa-
tients of the present study clearly indicates that the pathogene-
sis by which MRSA could lead to more rapid lung destruction
deserves more study. Staphylococci are known to be associated
with virulence factors, including membrane-damaging toxins
and invasins that promote bacterial spread in tissues. In one
study, only the PVL+ MRSA was associated with a higher
rate of decline of FEV1 [18]. An important limitation to our
study is that we did not perform molecular analysis on our
MRSA strains, hence we could not differentiate between
hospital-acquired and community-acquired MRSA.
Given the impact of MRSA on lung function decline and
survival, it seems reasonable to support the need for all CF cen-
ters to adopt a policy of segregation, infection control and erad-
ication. In 2008 the Cystic Fibrosis Trust published a
comprehensive report with specific recommendations for the
management of MRSA in CF centers including addressing seg-
regation, hygiene and surveillance [7]. Segregation and eradica-
tion have been shown to be successful in keeping the
prevalence of MRSA infection low [21], and minimize the like-
lihood of cross-infection. None of the MRSA positive patients
under study received eradication treatment, but they did receive
standard anti-MRSA treatment (vancomycin intravenously or
linezolid orally) when they were hospitalized for any infectious
exacerbation. We also obtain surveillance samples to detect car-
riers of MRSA and use segregation methods to minimize trans-
mission of MRSA between patients. Patients also have well-
ventilated single rooms with their own nebulizer compressor
system and oxygen delivery supplies.
Until now, eradication regimens to clear the MRSA positive
cultures are not routinely performed in our CF center. Based on
our findings and other recent reports it is probably justified to
start eradication therapy as soon as MRSA grows from respira-
tory cultures.
To the best of our knowledge this study, based on data from
the CF center of the University Hospital of Brussels, is the first
European study on this matter. We recognize the limitation that
our data originate from a relatively small sample of CF patients
and were collected retrospectively. Hence, generalization of
these results should be handled with caution, also because
strains and prevalence of MRSA may vary between countries.
This study may also have been affected by some biases that
should be taken into account when comparing with other stud-
ies. For instance, the two patient groups were matched for
chronic S. aureus colonization, age and gender; but not for sev-
eral other potential risk factors such as pancreatic insufficiency,
genotype, chronic P. aeruginosa colonization, or CFRD. Con-
cerning those last two variables, we found no statistically sig-
nificant difference between the MRSA and the control group;
but still these characteristics could play a role in the outcome
on lung function parameters. Misclassification of patients was
avoided by strict inclusion criteria (multiple MRSA negative
cultures in the year before entering the control group), and mi-
crobiologic laboratory misclassification was avoided by using
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fore, we did not perform molecular analyses on the MRSA
strains. To fully delineate the impact of MRSA colonization
on lung function, larger prospective longitudinal studies are
needed, which also link molecular characteristics of MRSA to
clinical outcomes.
In conclusion, we retrospectively analyzed 165 CF patients
with chronic positive S. aureus cultures over an 8-year period
to assess the effect of MRSA infection in CF on lung
function. Chronic colonization of MRSA amounted to 12.6%,
and MRSA acquisition was shown to be associated with time
spent in hospital, pancreatic insufficiency, genotype, and pre-
existing bronchiectasis. In addition, we observed consistent
trends of FEV1 decline over 2- to 6-year time intervals in
MRSA infected CF patients, indicating that an episode of
MRSA can entail a FEV1 decline that is almost double that pre-
dicted for CF patients who can remain unaffected by MRSA.
The present results prompt us to support the need for a more
pro-active policy of MRSA management of CF patients which
may include enhanced segregation, infection control and
eradication.
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